{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:29:47Z","timestamp":1787729387765,"version":"build-2784847793"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870125"],"award-info":[{"award-number":["81870125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>KMT2A\u2010Partial Tandem Duplication (KMT2A\u2010PTD) is a recurrent gene mutation present in acute myeloid leukemia (AML) and its prognostic significance needs to be clarified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three hundred and eighty\u2010seven consecutive adult newly diagnosed AML patients with non\u2010favorable cytogenetic risk were tested for KMT2A\u2010PTD by real\u2010time quantitative PCR. All patients were screened for AML\u2010related gene fusions and mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010two (8.3%) patients were identified as KMT2A\u2010PTD (+). KMT2A\u2010PTD significantly co\u2010occurred with FLT3\u2010ITD, RUNX1, and DNMT3A mutation and tended to be related to normal karyotype (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001, 0.019, and 0.062). Furthermore, none of the KMT2A\u2010PTD (+) patients had NPM1 mutation, CEBPA bZIP in\u2010frame mutation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005 and 0.0009), and none of them had KMT2A\u2010rearrangement and other gene fusions (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.16). As a result, all KMT2A\u2010PTD (+) patients were categorized into ELN2022\u2010intermediate or adverse groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). KMT2A\u2010PTD was not related to patients' age, sex, white blood cell (WBC) counts, hemoglobin (Hb) level, platelet (PLT) counts, percentage of bone marrow blast cells, and FAB subtypes (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). KMT2A\u2010PTD had no effect on complete remission achievement after 1 and 2 courses of induction therapy, relapse\u2010free survival, and overall survival in both the entire cohort and within the following five subgroups: FLT3\u2010ITD (+), RUNX1 mutation, DNMT3A mutation, ELN2022\u2010intermediate, and ELN2022\u2010adverse categories, respectively (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Moreover, KMT2A\u2010PTD (+) patients also could not be stratified by them (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>KMT2A\u2010PTD harbored its distinct genetic characteristics and had no prognostic impacts in AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijlh.14532","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:59:29Z","timestamp":1752573569000},"page":"1119-1127","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Characteristics and Outcomes of Adult Acute Myeloid Leukemia Patients With\n                    <scp>KMT2A<\/scp>\n                    \u2010Partial Tandem Duplication"],"prefix":"10.1111","volume":"47","author":[{"given":"Dai\u2010Hong","family":"Xie","sequence":"first","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hao","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling\u2010Di","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin\u2010Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao\u2010Yu","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Jun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-0946","authenticated-orcid":false,"given":"Ya\u2010Zhen","family":"Qin","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.10"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010693879"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280801"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752\u2010200207000\u201000004"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.13.6236"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2006.06301.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1535\u20106108(03)00214\u20109"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102005\u201001\u20100204"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201001\u2010134338"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401773"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.088"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10219"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402708"},{"issue":"7","key":"e_1_2_11_16_1","first-page":"881","article-title":"Risk Assessment by Monitoring Expression Levels of Partial Tandem Duplications in the MLL Gene in Acute Myeloid Leukemia During Therapy","volume":"90","author":"Weisser M.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404024"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201001\u2010069831"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001620\u20102"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428\u2010022\u201003430\u20104"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010008\u20100591\u20108"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238\u2010023\u201000995\u20105"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16535"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253\u20102727.2021.08.001"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217264"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000591\u20104"},{"key":"e_1_2_11_28_1","first-page":"865","article-title":"MLL\u2010PTD as a Marker for Minimal Residual Disease Studies: Quantification Counts","volume":"90","author":"Thiede C.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010021\u201009051\u20105"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2017.00004"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008\u2010733196"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.196"},{"key":"e_1_2_11_33_1","first-page":"262","article-title":"Trisomy 11 in Myeloid Malignancies Is Associated With Internal Tandem Duplication of Both MLL and FLT3 Genes","volume":"90","author":"Rege\u2010Cambrin G.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.1132"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25546"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201002\u2010412379"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5202"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.160"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1352091"},{"key":"e_1_2_11_40_1","first-page":"370","article-title":"Molecular Rearrangement of the ALL\u20101 Gene in Acute Myeloid Leukemia Without Cytogenetic Evidence of 11q23 Chromosomal Translocations","volume":"54","author":"Caligiuri M. A.","year":"1994","journal-title":"Cancer Research"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186890"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.14532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T03:33:26Z","timestamp":1762745606000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.14532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ijlh.14532"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.14532","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"2025-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}